Pancreatic cancer: New hopes after first line treatment

被引：24

作者：

Aroldi, Francesca ^{[1
]}

Bertocchi, Paola ^{[1
]}

Savelli, Giordano ^{[2
]}

Rosso, Edoardo ^{[3
]}

Zaniboni, Alberto ^{[1
]}

机构：

[1] Poliambulanza Fdn, Dept Med Oncol, Via Bissolati 57, I-25124 Brescia, Italy

[2] Poliambulanza Fdn, Dept Nucl Med, I-25124 Brescia, Italy

[3] Poliambulanza Fdn, Dept Gen Surg, I-25124 Brescia, Italy

来源：

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2016年 / 8卷 / 09期

关键词：

Nab-paclitaxel; Nal-iri; Pancreatic cancer; Second line; Algorithm; GEMCITABINE-PRETREATED PATIENTS; PLUS NAB-PACLITAXEL; PHASE-II TRIAL; 2ND-LINE THERAPY; FOLFIRINOX FAILURE; FOLINIC ACID; DOCETAXEL; MULTICENTER; OXALIPLATIN; ADENOCARCINOMA;

D O I：

10.4251/wjgo.v8.i9.682

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. Extensive research has yielded advances in first-line treatment strategies, but there is no standardized second-line therapy. In this review, we examine the literature trying to establish a possible therapeutic algorithm.

引用

页码：682 / 687

页数：6

共 46 条

[1] Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: A multicenter phase II study [J].

Androulakis, N ;

Syrigos, K ;

Polyzos, A ;

Aravantinos, G ;

Stathopoulos, GP ;

Ziras, N ;

Mallas, K ;

Vamvakas, L ;

Georgoulis, V .

CANCER INVESTIGATION, 2005, 23 (01) :9-12

[2]

[Anonymous], J CLIN ONCOL

[3]

[Anonymous], NCCN PANCR GUID

[4]

[Anonymous], J CLIN ONCOL S4

[5] Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma [J].

Astsaturov, Igor A. ;

Meropol, Neal J. ;

Alpaugh, R. Katherine ;

Burtness, Barbara A. ;

Cheng, Jonathan D. ;

McLaughlin, Sue ;

Rogatko, Andre ;

Xu, Zhiheng ;

Watson, James C. ;

Weiner, Louis M. ;

Cohen, Steven J. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (01) :70-75

[6] Successful Treatment with Nab-Paclitaxel and Gemcitabine after FOLFIRINOX Failure in a Patient with Metastasized Pancreatic Adenocarcinoma [J].

Berger, Anne K. ;

Weber, Tim F. ;

Jaeger, Dirk ;

Springfeld, Christoph .

ONKOLOGIE, 2013, 36 (12) :763-765

[7] Gemcitabine Plus Nab-paclitaxel as Second-line and Beyond Treatment for Metastatic Pancreatic Cancer: A Single Institution Retrospective Analysis [J].

Bertocchi, Paola ;

Abeni, Chiara ;

Meriggi, Fausto ;

Rota, Luigina ;

Rizzi, Anna ;

Di Biasi, Brunella ;

Aroldi, Francesca ;

Ogliosi, Chiara ;

Savelli, Giordano ;

Rosso, Edoardo ;

Zaniboni, Alberto .

REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) :142-145

[8] A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy [J].

Bodoky, Gyoergy ;

Timcheva, Constanta ;

Spigel, David Robert ;

La Stella, Phillip Joseph ;

Ciuleanu, Tudor Eliade ;

Pover, G. ;

Tebbutt, N. C. .

INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) :1216-1223

[9] Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer [J].

Brell, Joanna M. ;

Matin, Khalid ;

Evans, Terry ;

Volkin, Robert L. ;

Kiefer, Gauri J. ;

Schlesselman, James J. ;

Dranko, Shelley ;

Rath, Linda ;

Schmotzer, Amy ;

Lenzner, Diana ;

Ramanathan, Ramesh K. .

ONCOLOGY, 2009, 76 (04) :270-274

[10] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

← 1 2 3 4 5 →